DE69427704D1 - Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane - Google Patents

Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane

Info

Publication number
DE69427704D1
DE69427704D1 DE69427704T DE69427704T DE69427704D1 DE 69427704 D1 DE69427704 D1 DE 69427704D1 DE 69427704 T DE69427704 T DE 69427704T DE 69427704 T DE69427704 T DE 69427704T DE 69427704 D1 DE69427704 D1 DE 69427704D1
Authority
DE
Germany
Prior art keywords
amino
benzopyrane
fluor
disubstituted
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427704T
Other languages
English (en)
Other versions
DE69427704T2 (de
Inventor
Leslie Evenden
Maria Hammarberg
Sverker Hansson
Erik Hellberg
George Johansson
Rune Lundkvist
Bertil Ross
Dungan Sohn
Olov Thorberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69427704D1 publication Critical patent/DE69427704D1/de
Application granted granted Critical
Publication of DE69427704T2 publication Critical patent/DE69427704T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DE69427704T 1993-10-28 1994-10-26 Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane Expired - Fee Related DE69427704T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,671 US5420151A (en) 1989-12-22 1993-10-28 Chroman derivatives
PCT/SE1994/001010 WO1995011891A1 (en) 1993-10-28 1994-10-26 Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes

Publications (2)

Publication Number Publication Date
DE69427704D1 true DE69427704D1 (de) 2001-08-16
DE69427704T2 DE69427704T2 (de) 2002-05-02

Family

ID=22509617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427704T Expired - Fee Related DE69427704T2 (de) 1993-10-28 1994-10-26 Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane

Country Status (36)

Country Link
US (9) US5420151A (de)
EP (1) EP0725779B1 (de)
JP (1) JP3089276B2 (de)
CN (1) CN1062269C (de)
AT (1) ATE203019T1 (de)
AU (1) AU687115B2 (de)
BR (1) BR9407910A (de)
CA (1) CA2173257C (de)
CZ (1) CZ284371B6 (de)
DE (1) DE69427704T2 (de)
DK (1) DK0725779T3 (de)
EE (1) EE03253B1 (de)
ES (1) ES2160640T3 (de)
FI (1) FI961809A (de)
GR (1) GR3036816T3 (de)
HK (1) HK1002898A1 (de)
HR (1) HRP940890B1 (de)
HU (1) HUT75060A (de)
IL (1) IL111365A (de)
IS (1) IS1904B (de)
LV (1) LV12811B (de)
MY (1) MY111616A (de)
NO (1) NO314146B1 (de)
NZ (1) NZ275176A (de)
PL (1) PL178840B1 (de)
PT (1) PT725779E (de)
RU (1) RU2142951C1 (de)
SA (1) SA94150317B1 (de)
SG (1) SG52320A1 (de)
SI (1) SI0725779T1 (de)
SK (1) SK280527B6 (de)
TW (1) TW399049B (de)
UA (1) UA44717C2 (de)
WO (1) WO1995011891A1 (de)
YU (1) YU49048B (de)
ZA (1) ZA948353B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
NZ241495A (en) * 1991-02-08 1994-10-26 Lilly Co Eli 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromane derivative, preparation and pharmaceutical compositions thereof
WO1995013272A1 (fr) * 1993-11-10 1995-05-18 Japan Tobacco Inc. Derive de chromanne et utilisation therapeutique de ce dernier
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
SE9701438D0 (sv) 1997-04-17 1997-04-17 Astra Ab A new process
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US5962488A (en) 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
AU2002217742B2 (en) 2001-01-16 2008-02-21 Astrazeneca Ab Therapeutic heterocyclic compounds
US7032572B2 (en) * 2002-06-04 2006-04-25 Ford Global Technologies, Llc Method for controlling an engine to obtain rapid catalyst heating
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US20060205807A1 (en) * 2005-02-16 2006-09-14 Wyeth Amino-chroman compounds and methods for preparing same
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
RU2009126571A (ru) * 2006-12-12 2011-01-20 Биал-Портела Энд Ка, С.А. (Pt) Каталитический способ асимметричной гидрогенизации
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) * 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
EP3490607A4 (de) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. Verbindungen und zusammensetzungen und verwendungen davon
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
CA2972203C (en) 2017-06-29 2018-07-17 Exxonmobil Upstream Research Company Chasing solvent for enhanced recovery processes
CA2974712C (en) 2017-07-27 2018-09-25 Imperial Oil Resources Limited Enhanced methods for recovering viscous hydrocarbons from a subterranean formation as a follow-up to thermal recovery processes
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CA2978157C (en) 2017-08-31 2018-10-16 Exxonmobil Upstream Research Company Thermal recovery methods for recovering viscous hydrocarbons from a subterranean formation
CA2983541C (en) 2017-10-24 2019-01-22 Exxonmobil Upstream Research Company Systems and methods for dynamic liquid level monitoring and control
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
US20220317096A1 (en) * 2021-04-01 2022-10-06 Saudi Arabian Oil Company Residual corrosion inhibitor monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795874A (fr) * 1972-02-25 1973-08-23 Glaxo Lab Ltd Procede de preparation d'esters optiquement actifs d'alpha-amino-acides
JPS60152425A (ja) * 1984-01-20 1985-08-10 Oyo Seikagaku Kenkyusho:Kk ラセミ体の新規な光学分割法
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
PH22522A (en) * 1985-09-03 1988-10-17 Ciba Geigy Ag 3-amino-dihydro-1-benzopyrans and benzothiopyrans, their pharmaceutical compositions and method of using said compounds
FR2593504B1 (fr) * 1986-01-30 1988-12-09 Ile De France Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
US5026707A (en) * 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
IL93464A (en) * 1989-02-27 1996-10-16 Lilly Co Eli 2-Amino-1,2,3,4-Tetrahydronaplanin and 3 aminochromes with a transformed ring, a process for their preparation and pharmaceutical preparations containing them
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
RU2086535C1 (ru) * 1989-05-31 1997-08-10 Дзе Апджон Компани Производные 1,2,3,4-тетрагидро-2-нафтиламина
DE3942418A1 (de) * 1989-12-21 1991-06-27 Guenther Strecker Gestellstab
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
ATE149480T1 (de) * 1990-08-15 1997-03-15 Lilly Co Eli Ring-substituierte 2-amino-1,2,3,4-tetra- hydronaphthaline, 3-aminochromane und 3- aminothiochromane
HRP920935A2 (en) * 1991-10-08 1995-08-31 Astra Ab New therapeutically active compound

Also Published As

Publication number Publication date
CZ111496A3 (en) 1996-09-11
PL314086A1 (en) 1996-08-19
SK43696A3 (en) 1996-10-02
US5641807A (en) 1997-06-24
ATE203019T1 (de) 2001-07-15
NZ275176A (en) 1997-11-24
YU49048B (sh) 2003-07-07
CA2173257A1 (en) 1995-05-04
TW399049B (en) 2000-07-21
US5639784A (en) 1997-06-17
AU687115B2 (en) 1998-02-19
WO1995011891A1 (en) 1995-05-04
US5656657A (en) 1997-08-12
HRP940890A2 (en) 1996-12-31
US5500425A (en) 1996-03-19
LV12811B (en) 2002-08-20
CZ284371B6 (cs) 1998-11-11
UA44717C2 (uk) 2002-03-15
IL111365A (en) 2000-12-06
HU9601103D0 (en) 1996-06-28
CN1136811A (zh) 1996-11-27
ZA948353B (en) 1995-05-02
US5646309A (en) 1997-07-08
EP0725779A1 (de) 1996-08-14
AU8069794A (en) 1995-05-22
US5639772A (en) 1997-06-17
NO314146B1 (no) 2003-02-03
SA94150317B1 (ar) 2005-10-15
NO961687L (no) 1996-06-03
IL111365A0 (en) 1994-12-29
FI961809A (fi) 1996-05-20
EE03253B1 (et) 2000-02-15
HK1002898A1 (en) 1998-09-25
DK0725779T3 (da) 2001-10-29
BR9407910A (pt) 1996-11-26
LV12811A (en) 2002-04-20
SI0725779T1 (de) 2001-12-31
DE69427704T2 (de) 2002-05-02
YU62294A (sh) 1997-07-31
NO961687D0 (no) 1996-04-26
US5420151A (en) 1995-05-30
ES2160640T3 (es) 2001-11-16
FI961809A0 (fi) 1996-04-26
CA2173257C (en) 2005-12-06
PT725779E (pt) 2001-12-28
GR3036816T3 (en) 2002-01-31
EP0725779B1 (de) 2001-07-11
HRP940890B1 (en) 2001-12-31
US5656658A (en) 1997-08-12
RU2142951C1 (ru) 1999-12-20
HUT75060A (en) 1997-03-28
CN1062269C (zh) 2001-02-21
PL178840B1 (pl) 2000-06-30
SK280527B6 (sk) 2000-03-13
JP3089276B2 (ja) 2000-09-18
JPH09504287A (ja) 1997-04-28
SG52320A1 (en) 1998-09-28
MY111616A (en) 2000-09-27
US5650524A (en) 1997-07-22
IS1904B (is) 2003-11-20
IS4226A (is) 1995-04-29

Similar Documents

Publication Publication Date Title
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
SE9504661D0 (sv) New compounds
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DK0751939T5 (da) Naphthylamider som centralnervesystemmidler
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
SE9504662D0 (sv) New compounds
WO1996031208A3 (de) Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee